Denali Therapeutics Inc (DNLI)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$20.64
Buy
$20.73
$0.97 (+4.93%)
Prices updated at 03 Apr 2026, 00:58 EDT
| Prices minimum 15 mins delay
Prices in USD
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2025 | - |
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2026 | - |
| 2025 | - |
| 2024 | - |
| 2023 | 8.57 |
| 2022 | 30.86 |
| 2021 | 15.77 |
| 2020 | 366.63 |
| 2019 | 11.23 |
| 2018 | 557.26 |
| 2017 | - |
Price/Forward earnings (YTD)
-6.56
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2025 | -40.69 |
| 2024 | -33.45 |
| 2023 | -11.11 |
| 2022 | -22.76 |
| 2021 | -19.32 |
| 2020 | 6.59 |
| 2019 | -32.52 |
| 2018 | -6.31 |
| 2017 | -23.27 |
| 2016 | -56.31 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2025 | 1.13 |
| 2024 | 1.12 |
| 2023 | 1.12 |
| 2022 | 1.40 |
| 2021 | 1.46 |
| 2020 | 1.39 |
| 2019 | 1.40 |
| 2018 | 1.21 |
| 2017 | 1.04 |
| 2016 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
